Background {#Sec1}
==========

Nasopharyngeal carcinoma (NPC) is a type of malignant solid tumour which has been associated with multiple factors. One of the strong risk factors of NPC is Epstein--Barr virus (EBV) infection \[[@CR1], [@CR2]\]. A previous study has reported increased levels of immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies to EBV viral capsid antigen (VCA) and early antigen (EA) in NPC patients \[[@CR1]\]. Besides, a case--control study of NPC among Malaysian Chinese has reported that salted fish consumption during childhood was a significant risk factor for developing NPC \[[@CR3]\]. Mutagenic activity has been detected in the urine collected from experimental rats that were regularly fed with salted fish \[[@CR4]\]. In addition, Chinese salted fish was found to cause nasal cavity tumours in rats \[[@CR5], [@CR6]\]. These findings suggested the presence of carcinogenic substances in salted fish. Most studies pointed toward nitrosamines and nitrosamine precursors, which have been recognised as animal carcinogens \[[@CR7], [@CR8]\]. In addition, long-term exposures to intense industrial heat, formaldehyde, cigarette smoke and wood dust have also been found to be significantly associated with NPC \[[@CR3], [@CR9]--[@CR12]\]. Recently, chronic inflammation of sinonasal tract has been increasingly recognised as a risk factor for NPC \[[@CR13], [@CR14]\].

It is important to note that, all of these aetiological factors provoke the production of reactive oxygen species (ROS) \[[@CR15]--[@CR20]\]. Additionally, ROS was found to be involved in EBV reactivation in NPC cells after treatment with *N*-methyl-*N*′-nitro-*N*-nitroguanidine (MNNG) \[[@CR21]\]. The ROS-mediated EBV reactivation was inhibited by apigenin which has been suggested to be a potent ROS scavenger \[[@CR22]\]. Increased ROS may cause DNA double-strand breaks and error-prone repair. This may in turn lead to genomic instability \[[@CR23]\]. The cancer cells and inflammatory cells in stroma of NPC patients have been found to contain oxidative and nitrative DNA lesions \[[@CR24]\]. Oxidative stress may trigger apoptosis, a process of programmed cell death \[[@CR25]\]. We have previously demonstrated that oxidative stress-induced apoptosis resulted in chromosomal breakages in normal nasopharyngeal epithelial and NPC cells. In addition, the apoptotic nuclease, caspase-activated DNase (CAD) may be a major player in mediating these chromosomal breakages \[[@CR26]\].

Chromosomal breakage is an early event in both apoptotic DNA fragmentation and chromosome rearrangement. Previous studies revealed that chromosome breaks tend to fall within certain regions which contain specific chromatin structural elements, such as the matrix attachment region/scaffold attachment region (MAR/SAR) \[[@CR27], [@CR28]\]. MAR/SAR is the DNA sequence where the DNA loop structure binds to nuclear scaffold/matrix proteins \[[@CR29]\]. In the early stage of apoptosis, DNA cleavages take place at the base of the DNA loop \[[@CR30], [@CR31]\]. We hypothesised that H~2~O~2~-induced apoptosis may cause chromosomal breakages at MAR/SAR resulting in chromosome rearrangement in nasopharyngeal epithelial cells.

This study focuses on the *AF9* gene which is located at 9p22 because 9p22 is one of the deletion hotspots in NPC \[[@CR32]\]. The *AF9* gene is 280,880 bp in length. The nucleotide position of its exons and introns are shown in Additional file [1](#MOESM1){ref-type="media"}. Strissel et al. have identified two MAR/SARs within the *AF9* gene. These two MAR/SARs were designated as SAR1 and SAR2 \[[@CR28]\].

In the present study, in silico prediction of MAR/SAR sites was performed in the *AF9* gene. It was found that in the region that contains MAR/SAR (SAR region), the gene cleavage frequency of H~2~O~2~-treated cells was higher than that of the untreated control. On the contrary, in the region that does not contain MAR/SAR (non-SAR region), there was no significant difference in gene cleavage frequency between untreated and H~2~O~2~-treated cells. These observations are true for both normal nasopharyngeal epithelial and NPC cells. Moreover, the oxidative stress-induced chromosome breakages within the SAR region were reduced by caspase-3 inhibitor, which indirectly inhibits CAD. Our results suggested that MAR/SAR may play an important role in defining the location of chromosome breaks mediated by oxidative stress-induced apoptosis, where CAD is the essential nuclease. These chromosomal breakages may in turn lead to chromosome aberrations in nasopharyngeal epithelial cells.

Methods {#Sec2}
=======

Cell lines and chemicals {#Sec3}
------------------------

NP69 normal nasopharyngeal epithelial cell line and HK1 NPC cell line were kindly provided by Prof. Tsao Sai Wah (The University of Hong Kong, Hong Kong, China) and Prof. Lo Kwok Wai (The Chinese University of Hong Kong, Hong Kong, China). StemPro ACCUTASE Cell Dissociation Reagent, Keratinocyte-SFM medium, RPMI 1640 medium, penicillin, streptomycin, [l]{.smallcaps}-glutamine and fetal bovine serum were purchased from GIBCO, Invitrogen, USA. Camptothecin (CPT) was purchased from Santa Cruz Biotechnology, California, USA. Hydrogen peroxide (H~2~O~2~) was bought from MP Biomedicals, USA. Annexin V-Fluorescein isothiocyanate (FITC) Apoptosis Detection Kit I (BD Pharmingen™) and Flow Cytometry Mitochondrial Membrane Potential Detection Kit (BD™MitoScreen) were obtained from Becton--Dickinson Biosciences, USA. Caspase-Glo 3/7 Assay Kit and dNTP mix were purchased from Promega, USA. Caspase-3 inhibitor II (Z-DEVD-FMK) was obtained from Calbiochem, USA. Isoamyl alchohol was procured from Fluka, Switzerland. Sodium dodecyl sulfate (SDS) and phenol were bought from Amresco, USA. Ammonium acetate was from Merck, Germany. Chloroform was obtained from R&M Chemicals, UK. All the restriction enzymes, T4 DNA Ligase and DNA Polymerase I Large (Klenow) Fragment were purchased from New England Biolabs (NEB), USA. QIAquick Gel Extraction Kit and QIAquick Nucleotide Removal Kit were obtained from QIAGEN, Germany. Phusion High-Fidelity DNA Polymerase was obtained from Finnzymes, Finland. PCR primers were bought from First Base Laboratories.

In silico prediction of MAR/SARs {#Sec4}
--------------------------------

The whole sequence of the *AF9* gene was retrieved from Ensembl database \[EMBL:ENSG00000171843\]. The locations of experimentally isolated MAR/SAR, which were found within the *AF9* gene, were determined from the previous reports \[[@CR27], [@CR28]\]. Possible MAR/SAR sites were also identified using MAR/SAR recognition signature (MRS) which was suggested to be strongly associated with MAR/SAR \[[@CR33]\]. This MAR/SARs prediction was performed by using DNASTAR software (Lasergene, USA). The MRS comprises two nucleotide motifs that are within 200 bp apart. The first nucleotide motif is an 8 bp degenerate sequence, AATAAYAA while the second nucleotide motif is a 16 bp degenerate sequence, AWWRTAANNWWGNNNC, where Y = C or T; W = A or T; R = A or G; N = A, C, G or T. No mismatch is allowed within the 8 bp sequence whereas one mismatch is allowed within the 16 bp sequence. These two degenerate sequences should be within 200 bp apart. Each sequence can be aligned on either the Watson strand or the Crick strand. Either sequence can precede the other sequence. The sequences may even be overlapping. Clusters of more than one motif of either 8 or 16 bp within 200 bp apart are considered as a single MRS. Moreover, clusters of more than one MRS within close proximity are regarded as a single potential MAR/SAR site. The locations of the presently predicted MAR/SARs were compared with the locations of the experimentally extracted MAR/SARs reported in previous studies \[[@CR27], [@CR28]\].

In our in silico prediction of MAR/SAR which had been performed in the Abelson murine leukaemia viral oncogene homolog 1 (*ABL*) gene, there was only one MAR/SAR site predicted in the experimentally isolated SAR. The distance between 8 bp sequence element and the 16 bp sequence element was 248 bp (data not shown). Therefore, in this study, the maximal distance between 8 bp sequence element and the 16 bp sequence element was set at 250 bp.

Cell cultures {#Sec5}
-------------

NP69 cells were grown in Keratinocyte-SFM medium supplemented with 4--5 ng/ml recombinant Epidermal Growth Factor (rEGF), 40--50 µg/ml Bovine Pituitary Extract (BPE), 100 U/ml penicillin, 100 µg/ml streptomycin and 2% (v/v) heat-inactivated fetal bovine serum. HK1 cells were cultured in RPMI 1640 medium supplemented with 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% (v/v) heat-inactivated fetal bovine serum. Cells were incubated at 37 °C with 5% CO~2~.

Detection of phosphatidylserine (PS) externalisation {#Sec6}
----------------------------------------------------

NP69 cells (1.5 × 10^5^) were plated in 150 mm culture dishes and allowed to grow for 48 h. The NP69 cells were incubated with 100 µM of H~2~O~2~ for 16 and 24 h. HK1 cells (5.5 × 10^5^) were seeded in 150 mm culture dishes and allowed to grow for 72 h. The HK1 cells were incubated with 50 µM of H~2~O~2~ for 4 and 8 h. NP69 and HK1 cells treated with camptothecin (CPT) were used as positive controls. After exposure, the cells were harvested by using StemPro ACCUTASE Cell Dissociation Reagent. Annexin V-FITC Apoptosis Detection Kit I was used to detect PS externalisation in the harvested cells as previously described \[[@CR26]\].

Detection of mitochondrial membrane potential (MMP) disruption {#Sec7}
--------------------------------------------------------------

NP69 and HK1 cells were treated and harvested as described above. Flow Cytometry Mitochondrial Membrane Potential Detection Kit was used to detect the loss of MMP in the harvested cells as previously described \[[@CR26]\].

Nested IPCR detection of oxidative stress-induced chromosome breaks {#Sec8}
-------------------------------------------------------------------

### H~2~O~2~ treatment and genomic DNA extraction {#Sec9}

NP69 cells (2 × 10^4^) were plated in 60 mm culture dishes and allowed to grow for 48 h. The NP69 cells were incubated with H~2~O~2~ at concentration of 100 µM for 16 h. HK1 cells (8 × 10^4^) were seeded in 60 mm culture dishes and allowed to grow for 72 h. The HK1 cells were incubated with H~2~O~2~ at concentration of 50 µM for 8 h. After treatment with H~2~O~2~, genomic DNA extraction was carried out as previously described \[[@CR26]\].

### Manipulation of genomic DNA and nested IPCR for the AF9 SAR region {#Sec10}

The extracted genomic DNA was manipulated in preparation for nested IPCR as previously described \[[@CR26]\]. Additional file [2](#MOESM2){ref-type="media"} shows the simplified manipulation steps. Briefly, *Bam*H I digestion, Klenow fill-in, cyclisation and ethanol precipitation were performed. The DNA was then either digested with *Kpn* I or *Nde* I. QIAGEN QIAquick Nucleotide Removal Kit was used to clean up the DNA. Nested IPCR was carried out as previously reported \[[@CR26]\].

### Manipulation of genomic DNA and nested IPCR for the AF9 non-SAR region {#Sec11}

The manipulation steps were similar to the SAR region, except that *Hin*d III (RE2 in Additional file [2](#MOESM2){ref-type="media"}) and *Xba* I (RE3 in Additional file [2](#MOESM2){ref-type="media"}) were used for the *AF9* non-SAR region instead of *Kpn* I and *Nde* I. Cycle condition used in the first round of IPCR was as below: 30 s of 98 °C for 1 cycle (initial denaturation), followed by 30 cycles of 98 °C for 10 s (denaturation), 64 °C for 30 s (annealing), 72 °C for 22 s (extension), followed by 1 cycle of 72 °C for 10 min (final extension). Two microliter of fivefold diluted first round IPCR product was used for second round with similar cycle condition, except that the annealing temperature was 63 °C and the extension time was 15 s. The primers used for the first round of IPCR were 5′-TACCAAACATTTTGAGTCCTACAG-3′ (reverse) and 5′-GGCATTCAGGTGAGTAGTTTATTC-3′ (forward), whereas the primers used in the second round were 5′-AGCAGTAGACTTTTGTAACCTCAC-3′ (reverse) and 5′-AGGGGATGACTTTTCTTCAATC-3′ (forward).

Inhibition of caspase by Z-DEVD-FMK {#Sec12}
-----------------------------------

HK1 cells (8 × 10^4^) were seeded in 60 mm culture dishes and grown until 60--70% confluency. HK1 cells were either left untreated or pretreated with 50 μM of Z-DEVD-FMK for 1 h. The HK1 cells were then either left untreated or co-treated with 50 μM of H~2~O~2~ for 8 h. After incubation, genomic DNA was extracted as previously described \[[@CR26]\]. Following that, IPCR identification of the chromosome breaks within the *AF9* SAR and non-SAR regions was performed as described above.

Visualisation and DNA sequencing of the IPCR products {#Sec13}
-----------------------------------------------------

The IPCR products were loaded on 1% agarose gel. To analyse the IPCR bands, the gel was stained with ethidium bromide and visualised on an ultraviolet (UV) transilluminator (Vilber Lourmat, USA). QIAGEN QIAquick Gel Extraction Kit was used to clean up the IPCR bands which represent the cleaved fragments derived from the *AF9* SAR region. The purified IPCR bands were sequenced. By blasting the human genome database (Nucleotide BLAST, <http://blast.ncbi.nlm.nih.gov/Blast.cgi>), the sequencing results were annotated. To identify the position of the chromosome breaks, the sequencing results were aligned with the *AF9* gene sequence accessed from EMBL database \[EMBL:ENSG00000171843\] by using Seqman DNASTAR software (Lasergene, USA). The breakpoints identified were compared with the location of the experimentally extracted MAR/SARs reported in the previous study \[[@CR28]\] and the MRS predicted MAR/SARs. A genomic map was constructed to illustrate the position of the chromosome breaks relative to the location of the MAR/SARs.

Quantification of gene cleavage frequency {#Sec14}
-----------------------------------------

One to two sets of nested IPCR assays were performed for each experiment. Each set of IPCR assay consisted of five to eight IPCR replicates per cell sample. The number of IPCR bands which represent the DNA fragments derived from the cleaved *AF9* SAR and non-SAR regions was counted. Gene cleavage frequency expresses the median number of chromosome breaks detected within the *AF9* SAR region or non-SAR region in two to three independent experiments.

Statistical analysis {#Sec15}
--------------------

The Student's *t* test was used to assess the difference between untreated control and treated samples in the detections of PS externalisation and MMP disruption. The Mann--Whitney *U* test was used to analyse the difference between untreated control and treated samples in the nested IPCR assays. For the detections of PS externalisation and MMP disruption, data are presented as means and standard deviation (SD). For the IPCR assays, data are expressed as median and interquartile range (IQR). Differences were considered statistically significant at *p* value \< 0.05. All statistical tests are two-sided.

Results {#Sec16}
=======

In silico prediction of MAR/SAR {#Sec17}
-------------------------------

By using MRS, 29 possible MAR/SAR sites were predicted in the *AF9* gene. The nucleotide positions of the MRSs with their sequence composition, relative orientation, distance between the two sequence elements and location of the MRSs in the exon or intron of the *AF9* gene are shown in Table [1](#Tab1){ref-type="table"}. Out of the 29 predicted MAR/SAR sites, 14 were found in intron 2 (MAR/SARs 2--15 in Table [1](#Tab1){ref-type="table"}). Intron 2 is the largest intron of the *AF9* gene which is approximately 164 kb in length. Five MAR/SAR sites were predicted in each intron 3b (MAR/SARs 17--21 in Table [1](#Tab1){ref-type="table"}) and intron 4 (MAR/SARs 22--26 in Table [1](#Tab1){ref-type="table"}). Intron 7 was found to contain two potential MAR/SAR sites (MAR/SARs 27--28 in Table [1](#Tab1){ref-type="table"}). One MAR/SAR site was predicted in each intron 1 (MAR/SAR 1 in Table [1](#Tab1){ref-type="table"}), intron 3a (MAR/SAR 16 in Table [1](#Tab1){ref-type="table"}) and intron 9 (MAR/SAR 29 in Table [1](#Tab1){ref-type="table"}).Table 1MAR/SARs predicted within the *AF9* gene by using MRSPredicted MAR/SARAWWRTAANNWWGNNNC (16 bp)Nucleotide positionAATAAYAA (8 bp)Nucleotide positionDistance (bp)Location in exon/intron1ATAATAATAAAAGCCC (C)916--931AATAATAA (C)\
AATAATAA (C)915--922\
918--925Overlap\
OverlapIntron 12ATAGTAAGGATGGCTG (W)5636--5651AATAATAA (W)5694--570142Intron 23AAAATAACAAAGGAAG (W)10,555--10,570AATAACAA (W)10,561--10,568OverlapIntron 24AATATTATTATGGGTC (W)26,366--26,381AATAATAA (W)26,420--26,42738Intron 25AAAGTAAACTGGAAAC (C)47,851--47,866AATAACAA (W)47,627--47,634− 216Intron 26AAAATAATAATAATAC (W)56,224--56,239AATAATAA (W)\
AATAATAA (W)56,227--56,234\
56,230--56,237Overlap\
OverlapIntron 27AAAATCATCTTGGGAC (W)94,045--94,060AATAACAA (W)93,895--93,902− 142Intron 28AAAATAATAAAAACCC (C)108,633--108,648AATAATAA (C)108,635--108,642OverlapIntron 29-1ATAATAACATTTTACC (C)112,369--112,384AATAATAA (C)112,368--112,375OverlapIntron 29-2AAAATAATAATTGTAC (C)113,269--113,284AATAATAA (C)113,271--113,278OverlapIntron 210ATTGGAATGTAGAAAC (W)117,722--117,737AATAACAA (W)117,606--117,613− 108Intron 211-1AATATAATCTAATTGC (W)128,593--128,608AATAACAA (C)128,355--128,362− 230Intron 211-2AAAATAAGTTTCCAGC (W)129,838--129,853AATAACAA (C)\
AATAATAA (C)129,941--129,948\
129,980--129,98787\
126Intron 212ATAATAATAAAATCAC (W)136,176--136,191AATAATAA (W)136,182--136,189OverlapIntron 213AATATAATGAATATCC (C)139,927--139,942AATAATAA (C)\
AATAATAA (C)\
AATAATAA (C)\
AATAATAA (C)139,902--139,909\
139,905--139,912\
139,908--139,915\
139,911--139,918− 17\
− 14\
− 11\
− 8Intron 214TTTATAAACTTGTTTC (C)151,672--151,687AATAATAA (W)151,857--151,864169Intron 215AAAATAAAAAAGAGCT (C)158,541--158,556AATAATAA (W)158,593--158,60046Intron 216AAAATAATAAATACGC (W)170,523--170,538AATAATAA (W)\
AATAACAA (W)170,529--170,536\
170,619--170,626Overlap\
80Intron 3a17-1ATAATAAATATGAATA (W)178,638--178,653AATAATAA (W)178,634--178,641OverlapIntron 3b17-2AAAAGAACTAAGGTAC (W)179,378--179,393AATAATAA (W)179,140--179,147− 230Intron 3b18AAGGTAAATTAGCAGC (W)\
ATAATAATAATGTTCT (C)\
ATAATAATGTTCTACC (C)182,936--182,951\
183,171--183,186\
183,174--183,189AATAATAA (C)183,173--183,180221\
Overlap\
OverlapIntron 3b19ATTATAAGAAAAATTC (W)\
ATAATAAAAATGTTAT (C)\
ATAATGATCAAGTACC (C)191,065--191,080\
191,076--191,091\
191,548--191,563AATAATAA (W)191,323--191,330242\
231\
− 217Intron 3b20-1AAAATAAGAAAACATC (W)\
AATATAATTATGCTAA (W)194,333--194,348\
194,753--194,768AATAATAA (W)194,511--194,518162\
− 234Intron 3b20-2AATATAAAATTGCAAG (W)195,275--195,290AATAATAA (C)195,198--195,205− 69Intron 3b21AAAATAATAAAGCCAT (W)200,768--200,783AATAATAA (W)200,774--200,781OverlapIntron 3b22-1ATAATAATAATAATAC (W)215,365--215,380AATAATAA (W)\
AATAATAA (W)\
AATAATAA (W)215,368--215,375\
215,371--215,378\
215,374--215,381Overlap\
Overlap\
OverlapIntron 422-2AAAATAAAACTGACTC (C)\
ATAATTACATAGACAC (W)215,781--215,796\
216,113--216,128AATAACAA (C)215,941--215,948144\
− 164Intron 423ATAATAATAATGAAAG (C)227,849--227,864AATAATAA (C)\
AATAATAA (C)227,848--227,855\
227,851--227,858Overlap\
OverlapIntron 424-1ATAATAAGTTATAGGC (W)236,299--236,314AATAATAA (W)\
AATAATAA (C)236,308--236,315\
236,343--236,350Overlap\
28Intron 424-2AAAATAACAAAATGTC (W)\
AATGTAAGCAATATCC (W)237,605--237,620\
237,817--237,832AATAACAA (W)237,611--237,618Overlap\
− 198Intron 424-3AATGTAAGCAATATCC (W) AAAGTATTGTAGACCC (C)\
AAAATAATAAAGGGGT (W)237,817--237,832\
237,983--237,998\
237,995--238,010AATAATAA (W)238,001--238,008168\
2\
OverlapIntron 424-4TATATAATAAAGTGAC (C)238,794--238,809AATAATAA (W)239,050--239,057240Intron 425-1ATAATAATGAAGAAAG (C)246,610--246,625AATAATAA (C)246,588--246,595− 14Intron 425-2ATTGTAATATTGATTG (C)\
AATATTACAATGAATC (W)\
TTTATAAATTAGGGAC (W)247,587--247,602\
247,582--247,597\
247,758--247,773AATAACAA (C)247,561--247,568− 18\
− 13\
− 189Intron 426-1AAAGTAAATAAAAAAC (W)251,265--251,280AATAATAA (C)251,344--251,35163Intron 426-2AATGAAAGGAAGAGCC (W)\
ATAATAATAATGAAAA (C)252,636--252,651\
252,891--252,906AATAATAA (C)252,893--252,900241\
OverlapIntron 427ATAATAAACTACCATC (W)\
ATAATAATAAACTACC (W)\
AAAATAAACTATTTTC (C)262,931--262,946\
262,934--262,949\
263,198--263,213AATAATAA (W)262,940--262,947Overlap\
Overlap\
− 250Intron 728-1AATATAATCTTGAACG (C)265,612--265,627AATAATAA (C)265,768--265,775140Intron 728-2AAAATAAAAATATGCC (C)\
AATAAAAATATGCCCC (C)\
ATAATAAGGCTGGGAC (C)\
ATTTTAAGAATGAGTC (W)\
AAGATAAATTAGGTCC (C)266,963--266,978\
266,965--266,980\
267,134--267,149\
267,205--267,220\
267,317--267,332AATAATAA (C)267,133--267,140154\
152\
Overlap\
− 64\
− 176Intron 728-3AAGATAAATTAGGTCC (C)267,317--267,332AATAATAA (C)267,569--267,576236Intron 729AAAAAAAAATTGTAAC (W)273,593--273,608AATAACAA (W)273,528--273,535− 57Intron 9Nucleotide positions of the MRSs with their sequence composition, relative orientation (C: Crick strand and W: Watson strand), distance between the two sequence elements and location of the MRSs in the exon or intron of the *AF9* gene are shown. A negative distance indicates that 8 bp sequence element precedes the 16 bp sequence element

The distribution of the predicted MAR/SAR sites in the *AF9* gene is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Based on this in silico prediction of MAR/SAR, we determined a SAR region (contains MAR/SAR) and a non-SAR region (does not contain MAR/SAR) as the targeted regions of our study. The *AF9* SAR region contains four MRSs (MAR/SARs 24-1 to 24-4 in Table [1](#Tab1){ref-type="table"}). However, they are regarded as a single potential MAR/SAR site (MAR/SAR 24) because they were found in close proximity to each other (\< 1.5 kb). Three out of these four MRSs were found within the biochemically defined SAR1 (located in intron 4) \[[@CR28]\]. On the contrary, the *AF9* non-SAR region is a region which contains neither biochemically defined MAR/SAR nor MRS predicted MAR/SAR.Fig. 1Distribution of potential MAR/SAR sites predicted in the *AF9* gene. The *AF9* genomic map from nucleotide positions 601--281,480 is illustrated above \[EMBL:ENSG00000171843\]. The locations of exons 1 to 10 and *Bam*H I (B) restriction sites are shown. Green boxes indicate the two patient BCRs reported in the previous study. These two patient BCRs were denominated as BCR1 and BCR2 \[[@CR28]\]. Yellow boxes indicate the two MAR/SARs that were biochemically identified by Strissel and co-workers. These two MAR/SARs were designated as SAR1 and SAR2 \[[@CR28]\]. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in our study. Clusters of more than one MRS within close proximity are regarded as a single potential MAR/SAR site. Three MRSs were found in SAR1 (MAR 24-2, 24-3, 24-4). One MRS (MAR 27) has been predicted next to the SAR2. Based on the in silico prediction of MAR/SAR, a SAR region (contains MAR/SAR) and a non-SAR region (does not contain MAR/SAR) were determined to be the regions of study

Apoptosis detection in H~2~O~2~-treated NP69 and HK1 cells {#Sec18}
----------------------------------------------------------

By using flow cytometric analyses of PS externalisation and MMP disruption, significant percentages of apoptosis were detected in H~2~O~2~-treated NP69 and HK1 cells. These data have been reported in our previous study \[[@CR26]\]. Our findings indicate that H~2~O~2~ could induce apoptosis in NP69 and HK1 cells.

IPCR detection of chromosome breaks mediated by H~2~O~2~-induced apoptosis in NP69 cells {#Sec19}
----------------------------------------------------------------------------------------

To detect chromosome breaks within the *AF9* SAR and non-SAR regions in cells undergoing H~2~O~2~-induced apoptosis, nested IPCR assay was performed. In the SAR region, IPCR primers were designed to detect chromosome breaks within the first breakpoint cluster region of the *AF9* gene (BCR1). The *AF9* BCR1 is located at the telomeric end of intron 4. It is bordered by two biochemically defined MAR/SARs \[[@CR27], [@CR28]\]. The SAR region also contains one MRS predicted MAR/SAR (MAR/SAR 24 in Table [1](#Tab1){ref-type="table"}). The non-SAR region is a region which contains neither biochemically defined MAR/SAR nor MRS predicted MAR/SAR. The intact IPCR band for the *AF9* SAR region and non-SAR region are 944 bp (\~ 950 bp) and 956 bp (\~ 950 bp), respectively. If there is chromosome break within the region of study, for both SAR and non-SAR regions, IPCR band of less than 950 bp will be detected.

### AF9 SAR region {#Sec20}

As shown in Fig. [2](#Fig2){ref-type="fig"}a i, numerous IPCR bands smaller than 950 bp which represent the cleaved *AF9* gene were identified in NP69 cells treated with H~2~O~2~ (lanes 8--13). The untreated NP69 cells also show a few IPCR bands (lanes 3--7). By using flow cytometric analysis of phosphatidylserine (PS) externalisation, we detected a small amount of apoptotic cells in the untreated sample (\[[@CR26]\], Fig. [1](#Fig1){ref-type="fig"}). These apoptotic cells might undergo spontaneous DNA breaks and contribute to the background as seen in lanes 3--7. As summarised by the box plot in Fig. [2](#Fig2){ref-type="fig"}b, the median *AF9* cleavage frequency of H~2~O~2~-treated NP69 cells was 2.0-fold higher than that of the untreated control cells (*p* = 0.008). Our findings clearly indicate that H~2~O~2~-induced apoptosis results in cleavages within the *AF9* SAR region.Fig. 2Cleavage frequencies of the *AF9* SAR and non-SAR regions in H~2~O~2~-treated NP69 cells. **a** Representative gel pictures showing the IPCR results of the *AF9* gene in H~2~O~2~-treated NP69 cells: *i* SAR region, *ii* Non-SAR region. NP69 cells were either untreated (lanes 2--7) or treated with 100 µM of H~2~O~2~ for 16 h (lanes 8--13). The cells were harvested for gDNA extraction and nested IPCR. For each cell sample, six IPCR replicates (R1--R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the *AF9* gene. M: 100 bp DNA ladder. N: Negative control for IPCR. **b** *AF9* cleavage frequency detected in NP69 cells. Data are representative of three independent experiments. Each experiment consisted of 1--2 sets of IPCR. Each set of IPCR was performed in 5--8 IPCR replicates per cell sample. The results are presented as medians with IQRs. \**P *\< 0.05; NS: no significant difference (Mann--Whitney *U* test)

### AF9 non-SAR region {#Sec21}

As shown in Fig. [2](#Fig2){ref-type="fig"}a ii, numerous IPCR bands of less than 950 bp which represent the cleaved *AF9* gene were detected in both untreated NP69 cells (lanes 2--7) and NP69 cells treated with H~2~O~2~ (lanes 8--13). However, there was no significant difference between the untreated cells and H~2~O~2~-treated cells in the cleavage frequency of the *AF9* non-SAR region (*p* = 0.739) (Fig. [2](#Fig2){ref-type="fig"}b).

IPCR detection of chromosome breaks mediated by H~2~O~2~-induced apoptosis in HK1 cells {#Sec22}
---------------------------------------------------------------------------------------

### AF9 SAR region {#Sec23}

To further strengthen our observation that H~2~O~2~ could induce chromosome breaks within the *AF9* SAR region, IPCR detection of chromosome breaks was also performed in H~2~O~2~-treated HK1 cells. The representative gel picture in Fig. [3](#Fig3){ref-type="fig"}a i shows that more IPCR bands were identified in H~2~O~2~-treated HK1 cells (lanes 7--11) as compared with the untreated control cells (lanes 2--6). The median *AF9* cleavage frequency of H~2~O~2~-treated HK1 cells was 4.0-fold higher than that of the untreated control cells (*p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}b). These findings strengthen the suggestion that oxidative stress-induced apoptosis leads to *AF9* gene cleavages within the SAR region.Fig. 3Cleavage frequencies of the *AF9* SAR and non-SAR regions in H~2~O~2~-treated HK1 cells. **a** Representative gel pictures showing the IPCR results of the *AF9* gene in H~2~O~2~-treated HK1 cells: *i* SAR region, *ii* non-SAR region. HK1 cells were either untreated (lanes 2--6) or treated with 50 µM of H~2~O~2~ for 8 h (lanes 7--11). The cells were harvested for gDNA extraction and nested IPCR. For each cell sample, five IPCR replicates (R1--R5) were prepared. The side brackets show the IPCR bands derived from the cleavages of the *AF9* gene. M: 100 bp DNA ladder. N: Negative control for IPCR. **b** *AF9* cleavage frequency detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 1--2 sets of IPCR. Each set of IPCR was performed in 5--6 IPCR replicates per cell sample. The results are expressed as medians with IQRs. \**P *\< 0.05; NS: no significant difference (Mann--Whitney *U* test)

### AF9 non-SAR region {#Sec24}

As shown in Fig. [3](#Fig3){ref-type="fig"}a ii, numerous IPCR bands of less than 950 bp which represent the cleaved *AF9* gene were detected in both untreated HK1 cells (lanes 2--6) and H~2~O~2~-treated HK1 cells (lanes 7--11). However, there was no significant difference between the untreated HK1 cells and H~2~O~2~-treated HK1 cells in the cleavage frequency of the *AF9* non-SAR region (*p* = 0.405) (Fig. [3](#Fig3){ref-type="fig"}b). Taken together, our findings suggest that MAR/SAR sequence plays a crucial role in defining the location of chromosome breaks in H~2~O~2~-induced apoptosis.

In this study, we hypothesise that MAR/SAR is a preferential site of chromosome breaks. Therefore, less or no chromosome break was expected to be detected in this non-SAR region after H~2~O~2~ treatment. However, the current results are not as what was expected. There are obviously more cleavage bands detected in the non-SAR region compared with the SAR region (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). The box plot in Fig. [2](#Fig2){ref-type="fig"}b shows that in the untreated NP69 cells, the median cleavage frequency of the non-SAR region was 4.0-fold higher than that of the SAR region (*p* = 0.002). Similarly, in the untreated HK1 cells, the median cleavage frequency of the non-SAR region was 5.5-fold higher than that of the SAR region (*p* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}b). Such a difference might reflect that there are other chromatin structures which may also contribute to DNA fragility. In addition to MAR/SAR sequence, repeat elements have also been well implicated in mediating chromosome breaks \[[@CR27], [@CR34]\]. Hence, this prompted us to investigate the possibility of repeat elements in contributing to DNA fragility of the *AF9* non-SAR region.

Identification of repeat elements within the *AF9* gene {#Sec25}
-------------------------------------------------------

CENSOR program (<http://www.girinst.org/censor/>) was used to identify repeat elements in the *AF9* gene. The repeat elements identified within the SAR and non-SAR regions are shown in Table [2](#Tab2){ref-type="table"}. The locations of repeat elements identified within the SAR and non-SAR regions are illustrated in Fig. [4](#Fig4){ref-type="fig"}. There are 18 repeat elements identified within the 10.2 kb SAR region (Table [2](#Tab2){ref-type="table"}). Only one out of these 18 repeat elements is located within the amplified region. The region amplified by the reverse primer (AF9 236211 R) is from coordinates 236,059 to 236,211. This region does not contain any repeat element. The region amplified by the forward primer (AF9 245507 F) is from coordinates 245,507 to 246,292. ERE2_EH (coordinates 245,627--245,728, 102 bp in length) is the only one repeat element identified in this region. It occupies 11% (102 bp) of the amplified SAR region (944 bp).Table 2Repeat elements in the *AF9* SAR and non-SAR regions predicted by CENSOR program*AF9* regionsNucleotide positionPredicted repeat elementsFromToNameClassSAR region236,920236,987TWIFB1DNA/hAT237,423237,476MER20DNA/hAT237,491237,548hAT-80_HMDNA/hAT237,594237,636CR1-8_HMNonLTR/CR1237,637237,719L1ME4ANonLTR/L1238,883238,925GYPSY16-I_AGLTR/Gypsy239,516239,716MIRNonLTR/SINE239,786239,871ZAPHODDNA241,267241,318Polinton-1_XTDNA/Polinton241,475241,555Hoyak1DNA/hAT241,769241,847L4NonLTR/RTEX242,176242,276ATCOPIA38_ILTR/Copia242,849242,893BGLII_LTRERV/ERV2242,989243,024L1-1_ETNonLTR/L1243,397243,483ERV1-4-EC_IERV/ERV1244,480244,530hATw-2_SPDNA/hAT244,901245,043CHARLIE7DNA/hAT245,627245,728ERE2_EHInterspersed_RepeatNon-SAR region71,93671,999BEL1_MH-ILTR/BEL72,08172,368AluJr4NonLTR/SINE/SINE172,44772,695AluJInterspersed_Repeat73,45973,707MIRNonLTR/SINE73,70873,761TE-X-4_DRInterspersed_Repeat74,03074,304AluJbNonLTR/SINE/SINE174,89574,998CHARLIE5DNA/hAT75,00675,169CHARLIE5DNA/hAT75,19275,466AluJrNonLTR/SINE/SINE1The *AF9* SAR region is located at coordinates 236,059 to 246,292 \[Ensembl:ENSG00000171843\]. The nucleotide position, name and class of the predicted repeat elements are shown. The region amplified by the reverse primer (AF9 236,211 R) is from coordinates 236,059 to 236,211 while the region amplified by the forward primer (AF9 245,507 F) is from coordinates 245,507 to 246,292. The amplified SAR region contains one repeat element, namely ERE2_EH (at coordinates 245,627--245,728). The *AF9* non-SAR region is located at coordinates 71,116 to 75,277 \[Ensembl:ENSG00000171843\]. The nucleotide position, name and class of the predicted repeat elements are shown. The region amplified by the reverse primer (AF9 71,282 R) is from coordinates 71,116 to 71,282 while the region amplified by the forward primer (AF9 74,494 F) is from coordinates 74,494 to 75,277. The amplified non-SAR region contains three repeat elements, namely two CHARLIE5 (at coordinates 74,895--74,998 and 75,006--75,169) and one AluJr (at coordinates 75,192--75,466) Fig. 4The repeat elements identified within the *AF9* SAR and the non-SAR regions. **a** The SAR region. The SAR region which is bordered by two *Bam*H I sites is 10.2 kb in length (from coordinates 236,059 to 246,292). Green box represents the previously identified patient BCR which is indicated as BCR1. Yellow box shows the previously experimentally isolated MAR/SAR which is indicated as SAR1 \[[@CR28]\]. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in the present study. Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. Black boxes show the repeat elements predicted by CENSOR program. *Bam*H I (B), *Kpn* I (K) and *Nde* I (N) restriction sites are shown. **b** The non-SAR region. The non-SAR region which is bordered by two *Bam*H I sites is 4.2 kb in length (from coordinates 71,116 to 75,277). Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. Black boxes represent the repeat elements identified by using CENSOR program. *Bam*H I (B), *Hin*d III (H) and *Xba* I (X) restriction sites are shown

On the other hand, there are nine repeat elements identified within the 4.2 kb non-SAR region (Table [2](#Tab2){ref-type="table"}). Three out of these nine repeat elements are located within the amplified region. The region amplified by the reverse primer (AF9 71282 R) is from coordinates 71,116 to 71,282. There was no repeat element identified in this region. The region amplified by the forward primer (AF9 74494 F) is from coordinates 74,494 to 75,277. There are three repeat elements located in this region, namely two CHARLIE5 (coordinates 74,895--74,998, 104 bp in length and coordinates 75,006--75,169, 164 bp in length) and one AluJr (coordinates 75,192--75,466, 275 bp in length). These three repeat elements (the first CHARLIE5, 104 bp; the second CHARLIE5, 164 bp and AluJr, 275 bp) occupy 57% (543 bp) of the amplified non-SAR region (956 bp). In brief, given that there is no significant difference in the cleavage frequencies between the untreated and H~2~O~2~-treated cells, the chromosome breaks in the non-SAR region were most likely not mediated by H~2~O~2~-induced apoptosis. It is most likely that the presence of the repeat elements contribute to the DNA fragility of the non-SAR region.

Inhibition of caspase {#Sec26}
---------------------

### SAR region {#Sec27}

Figure [5](#Fig5){ref-type="fig"}a i, ii show the representative IPCR results of the *AF9* SAR region in H~2~O~2~-treated HK1 cells without and with caspase inhibitor (CI) pretreatment, respectively. In the absence of CI, the median cleavage frequency of the *AF9* gene detected in H~2~O~2~-treated HK1 cells was 4.0-fold higher than that of the untreated control cells (*p* \< 0.001) (Fig. [5](#Fig5){ref-type="fig"}b). The median cleavage frequency of the *AF9* SAR region in H~2~O~2~-treated HK1 cells with CI pre-treatment was 4.0-fold lower than that without CI pre-treatment (*p* = 0.004) (Fig. [5](#Fig5){ref-type="fig"}b). These results indicate that H~2~O~2~ induces cleavages within the *AF9* SAR region in a caspase-3-dependent manner.Fig. 5Caspase-3 inhibitor abolishes H~2~O~2~-induced cleavages within the *AF9* SAR region. **a** Representative gel pictures showing the IPCR analysis of the *AF9* SAR region in H~2~O~2~-treated HK1 cells: *i* without CI pre-treatment *ii* with CI pre-treatment. HK1 cells were left untreated or pre-treated with 50 µM of Z-DEVD-FMK for 1 h. The cells were then either untreated (lanes 2--7) or treated with 50 µM of H~2~O~2~ for 8 h (lanes 8--13). Genomic DNA was extracted and modified for nested IPCR. For each cell sample, six IPCR replicates (R1--R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the *AF9* gene. M: 100 bp DNA ladder. N: Negative control for IPCR. **b** Cleavage frequency of the *AF9* SAR region detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 1--2 sets of IPCR. Each set of IPCR was performed in 5--6 IPCR replicates per cell sample. The results are expressed as medians with IQRs. \**P* \< 0.05 (Mann--Whitney *U* test)

### Non-SAR region {#Sec28}

Figure [6](#Fig6){ref-type="fig"}a i, ii show the representative IPCR results of the *AF9* non-SAR region in H~2~O~2~-treated HK1 cells without and with CI pre-treatment, respectively. There is no significant difference in the cleavage frequency of the non-SAR region between the untreated control and H~2~O~2~-treated HK1 cells (*p* = 0.405) (Fig. [6](#Fig6){ref-type="fig"}b). There is also no significant difference in the cleavage frequency between the H~2~O~2~-treated HK1 cells without CI pre-treatment and that with CI pre-treatment (*p* = 0.390) (Fig. [6](#Fig6){ref-type="fig"}b). These findings show that CI has no significant effect on the cleavage frequency within the *AF9* non-SAR region. This implies that the cleavages of the non-SAR region are not dependent on caspase-3.Fig. 6Caspase-3 inhibitor shows no effect on reducing cleavages within the *AF9* non-SAR region. **a** Representative gel pictures showing the IPCR analysis of the *AF9* non-SAR region in H~2~O~2~-treated HK1 cells: *i* without CI pre-treatment *ii* with CI pre-treatment. HK1 cells were left untreated or pre-treated with 50 µM of Z-DEVD-FMK for 1 h. The cells were then either untreated (lanes 2--7) or treated with 50 µM of H~2~O~2~ for 8 h (lanes 8--13). Genomic DNA was extracted and modified for nested IPCR. For each cell sample, six IPCR replicates (R1--R6) were prepared. The side brackets show the IPCR bands derived from the cleavages of the *AF9* gene. M: 100 bp DNA ladder. N: Negative control for IPCR. **b** Cleavage frequency of the *AF9* non-SAR region detected in HK1 cells. Data are representative of two independent experiments. Each experiment consisted of 5--7 IPCR replicates per cell sample. The results are expressed as medians with IQRs. NS: No significant difference (Mann--Whitney *U* test)

Sequencing results {#Sec29}
------------------

Some of the IPCR bands detected within the *AF9* SAR region were excised, purified and sequenced. The sequencing results show that these fragments were all derived from the cleaved *AF9* gene (Additional file [3](#MOESM3){ref-type="media"}). Table [3](#Tab3){ref-type="table"} shows the position of chromosome breaks identified within the *AF9* SAR region in H~2~O~2~-treated NP69 and HK1 cells. Intriguingly, three chromosome breaks (at coordinates 245,560, 245,566 and 245,591) are identified within the *AF9* region (at coordinate 245,252--245,612) that was previously reported to translocate with the mixed lineage leukaemia (*MLL*) gene. This reciprocal translocation t(9;11)(p22;q23) resulted in the formation of *MLL*-*AF9* fusion gene in an acute lymphoblastic leukaemia (ALL) patient \[GenBank:AM050804\]. Seven breakpoints (at coordinates 245,560, 245,566, 245,591, 245,634, 245,645, 245,659 and 245,681) are within a distance of 70 nucleotides from the breakpoint identified in the ALL patient (at coordinate 245,612) \[GenBank:AM050804\]. A breakpoint mapped at coordinate 245,591 is similar with that identified in cultured normal blood cells treated with etoposide (VP16) (at coordinate 245,593) \[[@CR35]\]. A genomic map illustrating the positions of H~2~O~2~-induced chromosome breaks in NP69 and HK1 cells relative to the MAR/SAR sequences within the *AF9* gene is shown in Fig. [7](#Fig7){ref-type="fig"}.Table 3Breakpoints identified within the *AF9* SAR region in H~2~O~2~-treated cellsCell line treated with H~2~O~2~BreakpointRemarksNP69245,566This chromosome break was detected within the *AF9* region (at coordinates 245,252--245,612) which was previously found to take part in the *MLL*-*AF9* translocation in an ALL patient \[GenBank:AM050804\]. This breakpoint is 46 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,591This chromosome break was detected within the *AF9* region (at coordinates 245,252--245,612) which was previously found to take part in the *MLL*-*AF9* translocation in an ALL patient \[GenBank:AM050804\]. This breakpoint is two nucleotides different from that reported in cultured normal blood cells treated with VP16 (at coordinate 245,593) \[[@CR35]\] and 21 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,645This breakpoint is 33 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,659This breakpoint is 47 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,711245,730245,804245,817245,826245,842245,959245,970246,089HK1245,560This chromosome break was detected within the *AF9* region (at coordinates 245,252--245,612) which was previously found to take part in the *MLL*-*AF9* translocation in an ALL patient \[GenBank:AM050804\]. This breakpoint is 52 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,634This breakpoint is 22 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,681This breakpoint is 69 nucleotides different from that identified in an ALL patient (at coordinate 245,612) \[GenBank:AM050804\]245,755245,949The nucleotide positions of the chromosome breaks identified within the *AF9* SAR region were mapped according to the *AF9* sequence retrieved from Ensembl database \[EMBL:ENSG00000171843\] Fig. 7The positions of H~2~O~2~-induced chromosome breaks within the *AF9* SAR region. **a** The *AF9* genomic map from nucleotide positions 601--281,480 \[EMBL:ENSG00000171843\] \[[@CR26]\]. Black vertical lines represent the locations of exons 1--10. Green boxes show the two previously identified patient BCRs, namely BCR1 and BCR2 \[[@CR28]\]. Yellow boxes show the two MAR/SARs which were extracted experimentally in the previous study. These two MAR/SARs were indicated as SAR1 and SAR2 \[[@CR28]\]. *Bam*H I (B) restriction sites are shown. Yellow arrows represent the potential MAR/SAR sites predicted by MRS in our study. **b** The *AF9* SAR region (10.2 kb). *Bam*H I (B), *Kpn* I (K) and *Nde* I (N) restriction sites are shown. Green and blue arrows represent the primers used in the first and second rounds of nested IPCR, respectively. **c** Breakpoints mapped in H~2~O~2~-treated cells. Red and green vertical lines show the breakpoints identified in H~2~O~2~-treated NP69 and HK1 cells, respectively. All the chromosome breaks were mapped within BCR1 which is bordered SAR1 and SAR2. Blue box represents the *AF9* region (at coordinates 245,252--245,612) that was previously reported to translocate with the *MLL* gene resulting in the formation of the *MLL*-*AF9* fusion gene in an ALL patient \[GenBank:AM050804\]

Discussion {#Sec30}
==========

Much effort had been employed to identify tumor suppressor genes and oncogenes associated with NPC (reviewed in \[[@CR36], [@CR37]\]). However, the underlying mechanism of NPC chromosome rearrangement remains elusive. Oxidative stress has been well implicated in carcinogenesis \[[@CR38]\]. Most of the aetiological factors of NPC are known to induce oxidative stress \[[@CR15]--[@CR20]\]. In addition, oxidative stress is also a potent apoptotic inducer \[[@CR39]\]. Although apoptosis has long been recognised as a programmed cell death process \[[@CR40]\], the perception that cells undergoing apoptosis are destined to die has been challenged \[[@CR41]\]. It was shown that cells have the potential to recover from the execution phase of apoptosis through DNA repair. However, surviving cells that have undergone compromised DNA repair may carry chromosome rearrangements \[[@CR41], [@CR42]\].

In order to test the apoptotic effect of H~2~O~2~ in NP69 and HK1 cells, we analysed the H~2~O~2~-treated NP69 and HK1 cells by flow cytometric analyses of PS externalisation and MMP loss. Our observations showed that H~2~O~2~ could induce apoptosis in both NP69 and HK1 cells. These data have been published in our previous report \[[@CR26]\]. Chromosomal breakage resulting from chromosome loop excision is an initial event in both apoptotic DNA fragmentation and chromosome rearrangement. It was found that chromosome breaks tend to fall in certain regions containing specific chromatin structural elements such as MAR/SAR \[[@CR27], [@CR28]\]. MAR/SAR sequences possess unwinding properties which facilitate the entry of protein factors involved in apoptosis, replication, transcription and chromosome condensation \[[@CR43], [@CR44]\]. The unwinding properties of MAR/SAR sequences also render them to be more susceptible to cleavage \[[@CR44], [@CR45]\]. In our previous report, we demonstrated that high cell density and EBV latent membrane protein 1 (*LMP1*) expression triggered apoptosis in NPC cells. This in turn caused cleavages of the *MLL* BCR at the MAR/SAR sequence. These findings implied that MAR/SAR may play an essential role in defining the cleavage sites during high cell density or *LMP1*-induced apoptosis \[[@CR46]\]. In this study, we intended to investigate if MAR/SAR is a preferential site of chromosome breaks mediated by oxidative stress-induced apoptosis.

The human *AF9* gene at 9p22 was targeted in this study for two reasons. Firstly, this gene is one of the most common fusion partner genes of the *MLL* gene at 11q23 \[[@CR28]\]. The t(9;11)(p22;q23) has been strongly associated with acute myelogenous leukaemia (AML), less common with therapy-related AML (t-AML), with ALL and myelodysplastic syndromes (MDS) \[[@CR28], [@CR47]\]. Secondly, 9p22 is a common chromosomal deletion site in NPC \[[@CR32]\]. There were two MAR/SARs isolated experimentally in the *AF9* gene. They were designated as SAR1 and SAR2. SAR1 is found in intron 4, whereas SAR2 spans from exons 5 to 7. Two patient breakpoint cluster regions (BCR) have been identified in the *AF9* gene, namely, BCR1 and BCR2. BCR1 is located in intron 4, whereas BCR2 encompasses introns 7 to 8. These two BCRs are bordered by SAR1 and SAR2 \[[@CR27], [@CR28]\].

In the present study, in silico prediction of MAR/SAR was performed by using MRS. MRS is a bipartite sequence element that is specific for a large group of MAR/SARs. MRS consists of two individual sequence elements that are approximately 200 bp apart. However, when the DNA is wrapped around the histones, these two sequence elements are located at a position near the dyad axis of the nucleosome. Therefore, they can be aligned together in MAR/SAR after the nucleosomes are positioned. The close proximity between these two sequence elements on the positioned nucleosome enables them to create a protein binding site in MAR/SAR. In the study of van Drunen and co-workers, more than 300 kb of DNA sequence from several eukaryotic organisms were analysed. Their findings showed that all the MRSs that have been identified map specifically to the biochemically identified MAR/SARs \[[@CR33]\]. MRS has been widely used in previous studies. MRS has been used to predict MAR/SAR in the human *LMP*/*TAP* gene region. All of the five predicted MAR/SARs in the analysed region match to the experimentally defined MAR/SARs \[[@CR48]\]. Besides, MRS has also been used to identify the positions of MAR/SARs in human β-globin locus \[[@CR49]\] and wheat high-molecular-weight glutenin *1Dy10* gene promoter \[[@CR50]\].

The potential MAR/SAR sites predicted by MRS in the present study were compared with the location of biochemically identified MAR/SAR reported in previous studies \[[@CR27], [@CR28]\]. Strissel et al. have analysed 61 kb of the *AF9* region for MAR/SAR. Their region of study encompassed exons 4 to 10. In their region of study, two MAR/SARs were identified through experimental extraction. These two MAR/SARs were designated as SAR1 and SAR2. SAR1 is a 6.2 kb MAR/SAR located in intron 4 whereas SAR2 is a 4.6 kb MAR/SAR spans through parts of introns 5 to 7. To the extent of our knowledge, no analysis on MAR/SAR was reported for the *AF9* region from exon 1 to intron 3.

Within the *AF9* gene of 280,880 bp in length, 29 possible MAR/SAR sites were predicted in our study. Four MRSs (MAR/SARs 24-1 to 24-4 in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}) are associated with SAR1. However, these four MRSs are regarded as a single potential MAR/SAR site (MAR/SAR 24) because they cluster within close proximity to each other (\< 1.5 kb). Three out of these four MRSs fall within SAR1 (MAR/SARs 24-2 to 24-4 in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). One of the MRSs was found in a region \< 1 kb centromeric to SAR1 (MAR/SARs 24-1 in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). In addition, one MAR/SAR site (MAR/SAR 27 in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}) has been predicted in a region \< 1.5 kb telomeric to SAR2.

In the present study, both the normal transformed nasopharyngeal epithelial cells (NP69) and nasopharyngeal carcinoma cells (HK1) were used. In both of these cell lines, oxidative stress-induced apoptosis results in cleavages within the *AF9* SAR sequences. To relate the position of H~2~O~2~-induced chromosome breaks with the MAR/SAR sites, the IPCR bands that represent cleavages within the *AF9* SAR region were sequenced. The sequencing results revealed that all the chromosome breaks were mapped within BCR1 which is bordered by SAR1 and SAR2 (Fig. [7](#Fig7){ref-type="fig"}). Intriguingly, a few chromosome breaks were mapped within the region of *AF9* that was previously reported being involved in the formation of the *MLL*-*AF9* fusion gene in an ALL patient \[GenBank:AM050804\]. Similar chromatin structural elements have been identified in the BCRs of the *AF9* and *MLL* genes. These include DNase I hypersensitive (HS) cleavage sites, MAR/SAR sequences and topoisomerase II cleavage sites. The similarity in the structural elements is suggested to cause the *AF9* and *MLL* BCRs to be the recombination hotspots resulting in *MLL*-*AF9* translocations in leukaemia \[[@CR28]\]. Taken together, our results are consistent with those of the other studies which found that MAR/SAR may be a preferential site of chromosome breaks in apoptosis \[[@CR51]\] and chromosome rearrangements \[[@CR27]--[@CR29]\]. Considering the observations in leukaemic cells and nasopharyngeal epithelial cells, it is plausible that regardless of the cancer type, the chromatin structure could be playing a vital role in determining the site of chromosome rearrangement.

In order to further examine the involvement of MAR/SAR in stress-induced chromosome breaks formation, the cleavage frequency of the *AF9* SAR region was compared with that of the *AF9* non-SAR region. We hypothesised that MAR/SAR is a preferential site of chromosome breaks, thus we expected to see less or no chromosome breaks detected in the non-SAR region after H~2~O~2~ treatment. However, to our surprise, in both untreated NP69 and HK1 cells, the cleavage frequencies of the non-SAR region were significantly higher than those of the SAR region. These findings imply that there are other chromatin structures which may also contribute to DNA fragility. In addition to MAR/SAR sequence, repeat elements have also been strongly implicated in mediating chromosome breaks \[[@CR27], [@CR34]\]. Thus, the possibility of repeat elements in contributing to DNA fragility of the *AF9* non-SAR region was explored.

By using CENSOR program, three repeat elements (the first CHARLIE5, 104 bp; the second CHARLIE5, 164 bp and AluJr, 275 bp) were identified in the amplified non-SAR region of the *AF9* gene. These repeat elements occupy 57% (543 bp) of the amplified non-SAR region (956 bp). On the contrary, ERE2_EH (102 bp in length) is the only one repeat element identified in the amplified SAR region. It occupies 11% (102 bp) of the amplified SAR region (944 bp).

It is noteworthy that, although the cleavage frequency of the non-SAR region detected in the untreated cells was higher than that of the SAR region, there was no significant difference between the H~2~O~2~-treated cells and untreated cells in the cleavage frequency of the *AF9* non-SAR region. This is true for both NP69 and HK1 cells. Hence, it can be suggested that the cleavages identified in the non-SAR region were not stress-induced or stress-mediated. It is likely that the presence of repeat elements renders the chromosome to be more prone to cleavage. Previous studies have reported that common fragile sites, including FRA3B, FRA7G, FRA7H, FRA16D and FRAXB have all been shown to contain a high proportion of repeat elements, such as interspersed repeat elements, long terminal repeats (LTR), transposable elements, Mirs, L1 elements, L2 elements and *Alu* elements. These repetitive elements have been associated with the fragility of these fragile sites \[[@CR52], [@CR53]\]. The findings of our study conclude that MAR/SAR may be a preferential site of chromosome breaks during oxidative stress-induced apoptosis and may play an important role in oxidative stress-induced chromosome rearrangement.

We have previously demonstrated that H~2~O~2~ induces apoptosis in NP69 and HK1 cells in a caspase-3-dependent manner. By using Caspase-Glo 3/7, a luminescence-based assay, activation of caspase-3/7 was detected in H~2~O~2~-treated NP69 and HK1 cells. Pretreatment with Z-DEVD-FMK inhibits the activity of caspase-3/7 in H~2~O~2~-treated cells \[[@CR26]\]. In the cytoplasm of healthy cells, CAD exists naturally as a heterodimer with its chaperone, inhibitor of CAD (ICAD). ICAD possesses two caspase-3 cleavage sites. Upon caspase-3-mediated cleavage of ICAD, CAD is released from ICAD. Subsequently, CAD enters the nucleus and cleaves DNA by generating double-strand breaks \[[@CR54], [@CR55]\]. Given that ICAD is primarily inactivated by DEVD-cleaving caspase-3 \[[@CR56]\], inhibiting caspase-3 by using Z-DEVD-FMK is the most effective way of inactivating CAD. Therefore, if CAD is responsible for mediating chromosome breaks in H~2~O~2~-induced apoptosis, the chromosome breaks in H~2~O~2~-treated cells will be reduced or eliminated when caspase-3 is inhibited.

For the *AF9* SAR region, inhibition of caspase by Z-DEVD-FMK significantly reduced the *AF9* cleavages in H~2~O~2~-treated HK1 cells. Our findings suggest that, H~2~O~2~ induces chromosome breaks through caspase-3 activation. This study confirms the claims made in previous researches where H~2~O~2~ induces DNA fragmentation in a caspase-3-dependent manner \[[@CR39]\]. Given that activated caspase-3 can stimulate CAD which is responsible for apoptotic DNA fragmentation, CAD is most likely the major player responsible for H~2~O~2~-induced chromosome breaks within the *AF9* SAR region. Indeed, our previous study had demonstrated that, overexpression of ICAD resulted in expression of CAD and also inhibited H~2~O~2~-induced *MLL* gene cleavages. The observations of our previous study suggested a role for CAD in mediating H~2~O~2~-induced chromosome breaks \[[@CR57]\].

In addition, our findings were supported by other research that CAD preferentially binds to the nuclear matrix of cells undergoing apoptosis. CAD/ICAD complex is freely moving in dividing cells. However, once apoptosis is induced, the mobility of the activated CAD becomes gradually restricted. The immobilisation of CAD is due to its association with the nuclear matrix \[[@CR51]\]. Nuclear matrix is the binding site for the organisation of DNA loop structure \[[@CR58]\]. DNA interacts with the nuclear matrix through MAR/SAR sequences \[[@CR59]\]. When CAD binds to the nuclear matrix during apoptosis \[[@CR51]\], it is in close proximity to the MAR/SAR sequences of the DNA loops. Hence, CAD potentially cleaves the DNA at the MAR/SAR sequences when it is being associated with the nuclear matrix. The reduction of cleavages within the SAR region by inhibiting CAD thus supports our hypothesis that CAD cleaves the DNA preferentially at the MAR/SAR sites during oxidative stress.

By contrast, Z-DEVD-FMK shows no effect on reducing cleavages within the *AF9* non-SAR region. This indicates that the cleavages within the *AF9* non-SAR region are neither dependent on caspase-3 nor CAD. Since H~2~O~2~ induces apoptosis and chromosome breaks in a caspase-3-dependent manner, these findings therefore strengthen the evidence that the cleavages within the *AF9* non-SAR region are not mediated by H~2~O~2~-induced apoptosis.

In the current study, there are some limitations in using in silico prediction of MAR/SAR. The length and exact location of MAR/SAR could not be determined by using MRS-prediction. In order to study MAR/SAR in a more comprehensive way, biochemical isolation of MAR/SAR may be carried out simultaneously with in silico prediction in future works. This may be done by using a Southern blot-based SAR mapping assay \[[@CR28]\]. Nevertheless, the positions of MRS-predicted MAR/SAR may serve as a guide for designing suitable probes to identify biochemically isolated MAR/SAR. As for the comparison of SAR region and non-SAR region, more non-SAR regions may be studied. These could help further elucidate the roles of MAR/SAR in stress-induced chromosome breakages and rearrangements.

Conclusions {#Sec31}
===========

Our results clearly demonstrate that oxidative stress-induced apoptosis results in the *AF9* gene cleavages within the region that contains MAR/SAR. This implies that MAR/SAR may play an important role in defining the location of chromosomal cleavages during oxidative stress-induced apoptosis. In addition, the apoptotic nuclease CAD may be closely associated with MAR/SAR in mediating these oxidative stress-induced chromosomal cleavages. By investigating the role of MAR/SAR and its association with CAD, our findings provide deeper insights into the potential role of oxidative stress-induced apoptosis in mediating the chromosome rearrangements in nasopharyngeal epithelial cells.
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**Additional file 1.** Description of exons and introns in the *AF9* gene. **Additional file 2.** DNA manipulation steps in preparation for nested IPCR. **Additional file 3.** DNA sequencing data.

NPC

:   nasopharyngeal carcinoma

CAD

:   caspase-activated deoxyribonuclease

MAR/SAR

:   matrix association region/scaffold attachment region

MRS

:   MAR/SAR recognition signature

H~2~O~2~

:   hydrogen peroxide

PS

:   phosphatidylserine

MMP

:   mitochondrial membrane potential

IPCR

:   inverse polymerase chain reaction

BCR

:   breakpoint cluster region

MLL

:   mixed lineage leukaemia

ALL

:   acute lymphoblastic leukaemia

EBV

:   Epstein--Barr virus

ROS

:   reactive oxygen species

ICAD

:   inhibitor of caspase-activated deoxyribonuclease

CPT

:   camptothecin

VP16

:   etoposide

PI

:   propidium iodide

CI

:   caspase inhibitor
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